256 related articles for article (PubMed ID: 24607043)
1. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions.
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
J Allergy Clin Immunol Pract; 2014; 2(2):161-7. PubMed ID: 24607043
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013).
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):354-359.e2. PubMed ID: 26948485
[TBL] [Abstract][Full Text] [Related]
3. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors.
Epstein TG; Liss GM; Berendts KM; Bernstein DI
J Allergy Clin Immunol Pract; 2019; 7(6):1996-2003.e1. PubMed ID: 30776526
[TBL] [Abstract][Full Text] [Related]
4. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
Ann Allergy Asthma Immunol; 2013 Apr; 110(4):274-8, 278.e1. PubMed ID: 23535092
[TBL] [Abstract][Full Text] [Related]
5. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy.
Bernstein DI; Epstein TEG
Allergy Asthma Proc; 2020 Mar; 41(2):108-111. PubMed ID: 32122446
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma.
Epstein TG; Murphy-Berendts K; Liss GM; Bernstein DI
Ann Allergy Asthma Immunol; 2021 Jul; 127(1):64-69.e1. PubMed ID: 33753219
[TBL] [Abstract][Full Text] [Related]
7. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2.
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
Ann Allergy Asthma Immunol; 2011 Nov; 107(5):426-431.e1. PubMed ID: 22018614
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study.
Bernstein DI; Epstein T; Murphy-Berendts K; Liss GM
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):530-5. PubMed ID: 20568387
[TBL] [Abstract][Full Text] [Related]
9. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
[TBL] [Abstract][Full Text] [Related]
10. Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine.
Phillips JF; Lockey RF; Fox RW; Ledford DK; Glaum MC
Allergy Asthma Proc; 2011; 32(4):288-94. PubMed ID: 21781404
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010.
Santos N; Pereira AM; Silva R; Torres da Costa J; Plácido JL
Allergol Immunopathol (Madr); 2015; 43(1):25-31. PubMed ID: 24661594
[TBL] [Abstract][Full Text] [Related]
13. Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy.
Vidal C; Rodríguez Del Río P; Gude F; Casale T; Cox L; Just J; Pfaar O; Demoly P; Calderón MA
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1298-1305.e3. PubMed ID: 30557714
[TBL] [Abstract][Full Text] [Related]
14. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.
Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P;
Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250
[TBL] [Abstract][Full Text] [Related]
15. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment.
Albuhairi S; Sare T; Lakin P; El Khoury K; Crestani E; Schneider LC; Anzaldi R; Patterson A; Rachid R
J Allergy Clin Immunol Pract; 2018; 6(5):1711-1716.e4. PubMed ID: 29339129
[TBL] [Abstract][Full Text] [Related]
16. Vaccination during concurrent subcutaneous immunotherapy: safety of simultaneous application.
Ullrich D; Ullrich K; Mussler S; Thum-Oltmer S
Eur Ann Allergy Clin Immunol; 2015 Jan; 47(1):10-4. PubMed ID: 25599553
[TBL] [Abstract][Full Text] [Related]
17. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
[TBL] [Abstract][Full Text] [Related]
18. Safety of subcutaneous immunotherapy in patients with severe asthma.
Chow TG; Palka JM; Stone B; Trojan T; Epstein TG; Khan DA
Ann Allergy Asthma Immunol; 2022 Nov; 129(5):585-591.e3. PubMed ID: 35998846
[TBL] [Abstract][Full Text] [Related]
19. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.
Cox L; Larenas-Linnemann D; Lockey RF; Passalacqua G
J Allergy Clin Immunol; 2010 Mar; 125(3):569-74, 574.e1-574.e7. PubMed ID: 20144472
[TBL] [Abstract][Full Text] [Related]
20. Anaphylaxis: still a ghost behind allergen immunotherapy.
Makatsori M; Calderon MA
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):316-22. PubMed ID: 24873937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
